Gamida Cell to go private; Stoke aims to raise $75M
27 Mar 2024
Cell TherapyDrug ApprovalImmunotherapyAccelerated ApprovalClinical Study
Plus, news about a TUDCA study, PDS Biotechnology and Allarity Therapeutics:
Gamida Cell to go private: The commercial-stage cell therapy biotech will no longer trade on the Nasdaq after Highbridge Capital Management, its principal lender, restructures the company. The penny stock $GMDA was down 84% in Wednesday trading. Gamida secured FDA approval for its cell therapy Omisirge in April. Then, in January, it said it was “actively pursuing” alternative routes to keep going. — Kyle LaHucik
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.